Evidence map›Paper›PMID 42758149›Full record

ArticleOrganic & biomolecular chemistry2026

Chemoselective halogenation of premarineosin A for next-generation antimalarial development.

Natalia R Harris, Sahar Amin, Brian J Curtis, Awet A Teklemichael, Patricia Dranchak, Christina M McBride, Linnea Verhey-Henke, Chloe J Warrell, William M Dulaney, Erin N Oliphant and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Organic & biomolecular chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Natalia R HarrisLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.ORCID http://orcid.org/0000-0001-7583-7065
Sahar AminLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.
Brian J CurtisLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.
Awet A TeklemichaelLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD 20852, USA.
Patricia DranchakNational Center for Advancing Translational Sciences (NCATS), NIH, Rockville, MD 20852, USA.
Christina M McBrideLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.ORCID http://orcid.org/0000-0001-9487-1525
Linnea Verhey-HenkeLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.
Chloe J WarrellLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.
William M DulaneyLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.
Erin N OliphantNational Center for Advancing Translational Sciences (NCATS), NIH, Rockville, MD 20852, USA.
James IngleseNational Center for Advancing Translational Sciences (NCATS), NIH, Rockville, MD 20852, USA.
Xin-Zhuan SuLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD 20852, USA.
David H ShermanLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.ORCID http://orcid.org/0000-0001-8334-3647
Filipa PereiraLife Sciences Institute, University of Michigan, Ann Arbor, MI 48109, USA. fpere@umich.edu.ORCID http://orcid.org/0000-0002-0557-8480

Funding

Discovery and Characterization of Natural Product Systems-Research Supplement to Promote DiversityR35GM118101 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHERMAN, DAVID H · 2016 to 2025
$3.3M
Novel Molecular Modalities for Pharmacological Probe and Therapeutic Lead DiscoveryZIATR000495 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI INGLESE, JAMES · 2024 to 2025
$1.0M
Engineering Microbial Platforms for Sustainable Production and Derivatization of the Potent Antimalarial Premarineosin AR21AI202225 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Filipa Pereira, DAVID H SHERMAN · 2026 to 2026
$234k
Intramural NIH HHS ZIA TR000495NIAID NIH HHS F31 AI203140NIAID NIH HHS R21 AI202225NIGMS NIH HHS R35 GM118101
6 · The paper itself

Abstract

Premarineosin A undergoes rapid, chemoselective halogenation at C12 under mild conditions, enabling efficient access to brominated, chlorinated, fluorinated, and iodinated analogs without the need for protecting groups or extensive synthetic manipulation. Reaction conditions were optimized to favor selective functionalization of the electron-rich pyrrole ring while preserving the integrity of the macrocyclic scaffold. The resulting halogenated derivatives were readily isolated and characterized by LC-MS/MS and NMR spectroscopy. Biological evaluation revealed that all halogenated analogs retained potent antiplasmodial activity against both chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2)

Identifiers

PMID42758149
PMCPMC13588186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.